[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- Targeted Therapeutics is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau-targeted therapeutics encompass a broad class of investigational treatments designed to reduce, neutralize, or prevent the pathological accumulation of tau protein] in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and other tauopathies including [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [progressive supranuclear palsy[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--, and [corticobasal degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--. While [anti-amyloid therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics--TEMP--/mechanisms)--FIX-- such as [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX-- and [donanemab[/treatments/[donanemab[/treatments/[donanemab[/treatments/[donanemab--TEMP--/treatments)--FIX-- target the amyloid, tau-directed approaches aim to address the pathological cascade most closely correlated with neuronal death and cognitive decline [1][2].
Tau pathology] — including [hyperphosphorylation], aggregation into neurofibrillary tangles, and [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- through connected brain regions — correlates more strongly with neurodegeneration and cognitive decline than amyloid burden [3]. This has motivated intensive development of anti-tau strategies across multiple modalities: passive immunotherapy, antisense oligonucleotides, small-molecule aggregation inhibitors, and kinase inhibitors.
As of 2025, twelve anti-tau antibodies have entered clinical trials, with seven still in active clinical testing. No tau-targeted therapy has yet achieved regulatory approval, but promising biomarker data — particularly reduction of tau PET signal and CSF tau biomarkers — are encouraging continued development [2].
Anti-tau monoclonal antibodies represent the most advanced modality in tau-targeted drug development. These antibodies target different epitopes and forms of tau protein, aiming to neutralize extracellular tau species, block cell-to-cell tau propagation], or enhance clearance of intracellular tau aggregates.
The first generation of anti-tau antibodies targeted the N-terminal region of tau, based on the rationale that N-terminal fragments are abundant in CSF and may mediate intercellular tau transfer. However, these antibodies have been universally unsuccessful [4]:
Gosuranemab (BIIB092, Bristol-Myers Squibb): Targeted the N-terminal fragment of tau. Despite reducing CSF free N-terminal tau by up to 98%, gosuranemab failed to slow cognitive decline in Phase 2 trials in both AD and PSP. The disconnect between biomarker engagement and clinical efficacy suggested that N-terminal tau fragments may not be the pathologically relevant species.
Tilavonemab (ABBV-8E12, AbbVie): Also targeted N-terminal tau. Failed in Phase 2 trials for both PSP and AD, with no significant effect on clinical decline or tau PET signal.
Zagotenemab (LY3303560, Eli Lilly): A humanized version of the MC1 antibody targeting a conformational N-terminal epitope. Discontinued after failing Phase 2 in AD.
A systematic review and network meta-analysis comparing these four antibodies concluded that none demonstrated significant clinical benefit over placebo in AD patients [4].
Second-generation anti-tau antibodies target the microtubule-binding region (MTBR) or mid-domain of tau, which is more directly involved in aggregation and prion-like seeding. These approaches show more promising preclinical and early clinical data [2]:
E2814 (Etalanetug, Eisai): A human IgG1 antibody that binds to MTBR-tau, specifically targeting the region involved in tau aggregation and cell-to-cell spreading. In the Phase 1b Study 103 conducted in dominantly inherited AD (DIAD) patients, E2814 demonstrated [5]:
E2814 is currently being evaluated in the [DIAN]-TU Tau NexGen Platform Study (Phase 2/3), with results expected around 2027. It is also being studied in combination with [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX-- to test whether simultaneous amyloid and tau targeting produces synergistic benefit.
JNJ-63733657 (Posdinemab, Johnson & Johnson): Targets the phosphorylated mid-domain region of tau ([p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- epitope). Phase 2 data expected by end of 2025. [In Phase 1, posdinemab significantly reduced CSF [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- levels, suggesting target engagement with the most pathologically relevant phosphorylated tau species [2].
Bepranemab (UCB0107, UCB): Targets the mid-domain of tau (residues 235-246), involved in cell-to-cell propagation. The Phase 2a TOGETHER trial results, presented at CTAD 2024 [6]:
Semorinemab (Genentech/AC Immune): An IgG4 antibody targeting extracellular tau with reduced effector function. The Phase 2 LAURIET trial in mild-to-moderate AD showed slowing on one cognitive test (ADAS-Cog) but no improvement on other cognitive or functional outcomes [7]. Genentech ended its collaboration with AC Immune in January 2024.
Antisense oligonucleotides offer a fundamentally different approach: rather than targeting existing tau protein, ASOs reduce tau production at the mRNA level by promoting degradation of [MAPT gene] transcripts via RNase H-mediated cleavage [8].
BIIB080 (IONIS-MAPTRx, Biogen/Ionis): The most advanced tau ASO, currently in Phase 2. This [antisense oligonucleotide[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX-- targets [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mRNA in the central nervous system and is administered intrathecally [8]:
The advantage of ASOs over immunotherapy is their ability to reduce both intracellular and extracellular tau by blocking production at the source. However, intrathecal administration (lumbar puncture) is more burdensome than IV or SC antibody infusions.
NIO752 (Novartis): Another anti-[MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- ASO in early clinical development with an alternative chemical modification for enhanced potency and durability.
Small molecules that directly inhibit tau aggregation offer the potential for oral administration but have faced significant challenges [1]:
LMTX (Hydromethylthionine mesylate, TauRx): A methylthioninium derivative that inhibits tau aggregation. In Phase 3 trials, LMTX failed as an add-on therapy to existing AD treatments. However, post-hoc analyses suggested possible benefit as monotherapy. A subsequent trial (LUCIDITY) in mild cognitive impairment is evaluating LMTX as monotherapy, with mixed preliminary results. The clinical development of LMTX remains controversial.
Tau hyperphosphorylation] is driven by several kinases, including [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX--, [CDK5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5--TEMP--/entities)--FIX--, and Fyn kinase. Targeting these kinases could reduce pathological tau phosphorylation:
The challenge with kinase inhibitors is selectivity — [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- and [CDK5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5--TEMP--/entities)--FIX-- have hundreds of substrates beyond tau, and broad kinase inhibition causes dose-limiting toxicity.
Beyond phosphorylation, tau undergoes acetylation, ubiquitination, SUMOylation, and O-GlcNAcylation. Modulating these modifications represents an emerging strategy:
Active immunization approaches aim to induce the patient's own immune system to produce anti-tau antibodies:
A growing consensus in the field holds that targeting tau alone — or amyloid alone — may be insufficient for meaningful disease modification. Combination strategies are being actively pursued [1]:
The most promising combination approach pairs amyloid-clearing antibodies with tau-targeting agents. The rationale is that amyloid pathology drives tau spreading, so removing amyloid upstream while simultaneously blocking tau propagation could produce synergistic benefit:
Combining tau-targeting with [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- modulation could address the inflammatory amplification of tau pathology. [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- can measure treatment effects on tau burden in vivo.
The study of Tau Targeted Therapeutics has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.